India’s customs, ports go digital to stop substandard medical imports

The Indian government has launched an initiative to link all 34 officially notified ports, including those for sea, air, rail, and road transport, with the ICEGATE digital customs platform in order to combat the import of substandard drugs and medical devices. Under a new directive from the Central Drugs Standard Control Organisation (CDSCO), only these designated entry points are now authorized for the import of such products, in accordance with Rule 43-A of the Drugs Rules, 1945. CDSCO offices across India are digitally mapped to these notified ports through ICEGATE to help standardize and monitor regulatory processing.

The ICEGATE system, operated by the Central Board of Indirect Taxes and Customs, serves as an electronic gateway for the submission, processing, and clearance of import and export documents such as Bills of Entry. When an importer files a Bill of Entry for drugs or medical devices, the document is automatically routed to the appropriate CDSCO port office via ICEGATE for compliance checks and regulatory approvals prior to customs clearance. This integration allows for real-time tracking, online payment of customs duties, and communication of compliance decisions between customs and regulatory agencies, reducing manual oversight and the opportunity for non-compliant items to slip through.

By limiting entry to these mapped ports and leveraging the ICEGATE portal’s tracking, assessment, and risk management capabilities, authorities can block imports of defective or non-compliant products more effectively. This strengthens quality enforcement for drugs and medical devices, ensures regulatory transparency, supports the safe supply of medical products, and aligns with India’s broader policy focus of reducing import dependence in the healthcare sector.
MB Bureau